Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name Etoposide
Synonyms
Therapy Description

Vepesid (etoposide) binds to and inhibits DNA topoisomerase II, resulting in accumulated DNA damage, inhibition of replication, and cell death (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Etoposide Vepesid EPEG|Eposin|VP-16|VP-16-213 TOPO2 inhibitor 5 Vepesid (etoposide) binds to and inhibits DNA topoisomerase II, resulting in accumulated DNA damage, inhibition of replication, and cell death (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT06564844 Phase III Tegafur-gimeracil-oteracil Potassium Etoposide AZD2936 + Datopotamab deruxtecan Carboplatin AZD2936 Vinorelbine Pemetrexed Disodium Cisplatin A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12) Recruiting USA | TUR | SWE | POL | NLD | ITA | HUN | GBR | FRA | ESP | DEU | CHE | CAN | BRA | BEL 7
NCT03319901 Phase I Cytarabine Mercaptopurine Methotrexate Cyclophosphamide Venetoclax Doxorubicin Etoposide Vincristine Sulfate Venetoclax and Chemotherapy In ALL Recruiting USA 0
NCT03141359 Phase II Paclitaxel Cisplatin Durvalumab Carboplatin Etoposide Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC Active, not recruiting USA 0
NCT03164057 Phase II Etoposide Filgrastim Dexrazoxane Daunorubicin Idarubicin Fludarabine Asparaginase Cytarabine Sorafenib Mitoxantrone Decitabine Azacitidine A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting USA 0
NCT01526603 Phase I Melphalan Etoposide Filgrastim Tretinoin Carboplatin High Dose Chemotherapy and Autologous Transplant for Neuroblastoma Completed USA 0
NCT03117751 Phase II Cyclophosphamide Vincristine Sulfate Idarubicin Blinatumomab Doxorubicin Clofarabine Vorinostat Ruxolitinib Prednisone Bortezomib Etoposide Dasatinib Daunorubicin Dexamethasone Rituximab Methotrexate Cytarabine Mercaptopurine Pegaspargase Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma Active, not recruiting USA | AUS 0
NCT02512926 Phase I Cyclophosphamide Carfilzomib Etoposide Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children Completed USA | CAN 0
NCT00074490 Phase II Cyclophosphamide Cyclosporine Rituximab Doxorubicin Etoposide Filgrastim Vincristine Sulfate Fludarabine Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers Terminated USA 0
NCT04380636 Phase III Carboplatin Pemetrexed Disodium Pembrolizumab Cisplatin Durvalumab Etoposide Olaparib + Pembrolizumab Paclitaxel Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) Active, not recruiting USA | TUR | ROU | POL | NOR | LVA | LTU | ITA | HUN | GBR | FRA | EST | ESP | DEU | CZE | CAN | ARG 9
NCT02112916 Phase III Cyclophosphamide Vincristine Sulfate Ifosfamide Pegaspargase Methotrexate Cytarabine Mercaptopurine Thioguanine Leucovorin Daunorubicin Dexamethasone Bortezomib Etoposide Doxorubicin Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma Active, not recruiting USA | NZL | CAN | AUS 0
NCT02432274 Phase Ib/II Etoposide Lenvatinib Cyclophosphamide Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies Completed USA | ITA | GBR | FRA | ESP | DEU 0
NCT01356290 Phase II Thalidomide Fenofibrate Etoposide Bevacizumab Celecoxib Cyclophosphamide + Cytarabine Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma (MEMMAT) Recruiting USA | SWE | NOR | FRA | ESP | DNK | AUT 1
NCT01450761 Phase III Cisplatin Ipilimumab Carboplatin Etoposide Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone Completed USA | SWE | ROU | POL | NLD | ITA | ISR | IRL | HUN | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG 13
NCT03023046 Phase II Rituximab Doxorubicin Etoposide Imatinib Dasatinib Cyclophosphamide Prednisone Vincristine Sulfate Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Completed USA 0
NCT02815592 Phase Ib/II Etoposide BMS-986012 + Cisplatin + Etoposide BMS-986012 + Carboplatin + Etoposide Trial of BMS-986012 in Combination With Platinum and Etoposide Completed ESP 0
NCT03793478 Phase Ib/II Etoposide Cytarabine + Fludarabine + Methotrexate + Prednisolone + Quizartinib Cytarabine + Daunorubicin + Fludarabine + Methotrexate + Prednisolone + Quizartinib Cytarabine + Daunorubicin + Fludarabine + Hydrocortisone + Methotrexate + Quizartinib Cytarabine + Fludarabine + Methotrexate + Prednisolone Quizartinib Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood Active, not recruiting USA | SWE | NLD | ITA | ISR | FRA | ESP | DNK | CAN | BEL 0
NCT02489903 Phase II Etoposide RRx-001 Carboplatin Cisplatin Nab-paclitaxel RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens Completed USA 0
NCT02883049 Phase III Dasatinib Dexamethasone + Doxorubicin Prednisone Vincristine Sulfate Thioguanine Cytarabine Mercaptopurine Leucovorin Methotrexate Pegaspargase Etoposide Clofarabine Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations Active, not recruiting USA | NZL | IRL | CHE | CAN | AUS 1
NCT02553460 Phase II Cyclophosphamide Mitoxantrone Dexamethasone Bortezomib Etoposide Vincristine Sulfate Pegaspargase Vorinostat Cytarabine Methotrexate Leucovorin Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I Active, not recruiting USA | CAN 0
NCT03126916 Phase III Doxorubicin 131I-MIBG Sargramostim Etoposide Melphalan Busulfan Isotretinoin Vincristine Sulfate Cisplatin Cyclophosphamide Thiotepa Dexrazoxane Lorlatinib Carboplatin Aldesleukin Topotecan Dinutuximab Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) Active, not recruiting USA | CAN 1
NCT01042522 Phase II Carboplatin Cisplatin Paclitaxel Etoposide Bleomycin Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors Unknown status USA 0
NCT04989283 Phase II Carboplatin Atezolizumab + Cisplatin Atezolizumab + Paclitaxel Atezolizumab + Etoposide Cisplatin Etoposide Paclitaxel Atezolizumab + Carboplatin Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer Withdrawn USA 0
NCT06528496 Phase II Irinotecan Doxorubicin Ifosfamide Sargramostim Etoposide Temozolomide Carboplatin Naxitamab Vincristine Sulfate Topotecan Cyclophosphamide N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma Recruiting USA 0
NCT02043587 Phase II Rituximab Pegaspargase Methotrexate Cytarabine Leucovorin Cyclophosphamide Dasatinib Daunorubicin Vincristine Sulfate Etoposide Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma Terminated USA 0
NCT02153580 Phase I Etoposide Cyclophosphamide + Fludarabine Bendamustine Cellular Immunotherapy Following Cyclophosphamide in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia Active, not recruiting USA 0
NCT02653196 Phase II Thiotepa Etoposide Alemtuzumab Palifermin Fludarabine + Melphalan Cyclosporine + Mycophenolate mofetil + Tacrolimus A Multi-Institutional Phase II Feasibility Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors Terminated USA 0
NCT03020030 Phase III Nelarabine Dexrazoxane Asparaginase Vincristine Sulfate Cyclophosphamide Cytarabine Mercaptopurine Pegaspargase Methotrexate Etoposide Doxorubicin Dexamethasone Prednisone Dasatinib Leucovorin Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents Active, not recruiting USA | CAN 0
NCT03113500 Phase II Etoposide Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone Doxorubicin Cyclophosphamide Prednisone Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma Active, not recruiting USA | CAN 0
NCT01859741 Phase Ib/II Cisplatin Etoposide Carboplatin Tarextumab A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Platinum Therapy in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE) Terminated USA 0
NCT03860844 Phase II Idarubicin Cyclophosphamide Isatuximab Doxorubicin Etoposide Daunoxome Cytarabine Methotrexate Daunorubicin Fludarabine Dexamethasone Mitoxantrone Filgrastim Vincristine Sulfate Pegaspargase Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia Terminated USA | SWE | NOR | NLD | ITA | HUN | GRC | FRA | DNK | DEU | BRA | ARG 4
NCT03007147 Phase III Pegaspargase Methotrexate Leucovorin Cytarabine Mercaptopurine Thioguanine Vincristine Sulfate Cyclophosphamide Imatinib Ifosfamide Dexrazoxane Daunorubicin Dexamethasone Methylprednisolone Etoposide Prednisolone Doxorubicin Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Active, not recruiting USA | SWE | NZL | NLD | ITA | ISR | FRA | FIN | DEU | CZE | CHE | CAN | BEL | AUT | AUS 4
NCT00936936 Phase II Gemcitabine Ifosfamide Etoposide Melphalan Etoposide + Ifosfamide Docetaxel + Gemcitabine + Melphalan Bevacizumab + Carboplatin High-dose Chemotherapy for Poor-prognosis Relapsed Germ-Cell Tumors Completed USA 0
NCT03004287 Phase II Melphalan Carfilzomib Cisplatin Cyclophosphamide Lenalidomide Dexamethasone Daratumumab Bortezomib Etoposide Doxorubicin Thalidomide 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy Active, not recruiting USA 0
NCT02299518 Phase I Etoposide Selinexor Cytarabine + Etoposide + Mitoxantrone Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed USA 0
NCT02521493 Phase III Etoposide Thioguanine Cytarabine Asparaginase Erwinia chrysanthemi mitoxantrone hydrochloride Daunorubicin Asparaginase Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome Active, not recruiting USA | NZL | CAN | AUS 2
NCT01614197 Phase I Etoposide Cyclophosphamide Prednisone Cytarabine Temsirolimus Methotrexate A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma Completed USA | CAN | AUS 0
NCT02551718 Phase I Bosutinib Irinotecan Romidepsin Busulfan Melphalan Nilotinib Crizotinib Cytarabine Mitoxantrone Dasatinib Pazopanib Paclitaxel Clofarabine Hydroxyurea Tretinoin Carfilzomib Nelarabine Bexarotene Pentostatin Everolimus Cabozantinib Mercaptopurine Methotrexate Cladribine Thioguanine Daunorubicin Ponatinib Etoposide Afatinib Gefitinib Gemcitabine Regorafenib Arsenic trioxide Trametinib Imatinib Erlotinib Dabrafenib Decitabine Axitinib Azacitidine Ruxolitinib Fludarabine Lapatinib Ceritinib Sirolimus Sorafenib Lomustine Sunitinib Cabazitaxel Temsirolimus Topotecan Bortezomib Pralatrexate High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia Completed USA 0
NCT03136146 Phase II Cyclophosphamide Bortezomib Etoposide Rituximab Ofatumumab Clofarabine Pegfilgrastim Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL) Recruiting USA 0
NCT04364048 Phase II Pemetrexed Disodium Durvalumab Paclitaxel Etoposide Docetaxel Carboplatin Cisplatin Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT02788201 Phase II Erlotinib Thiotepa Imatinib Dacarbazine Arsenic trioxide Idarubicin Mitomycin C Thioguanine Mercaptopurine Methotrexate Cladribine Epirubicin Gemcitabine Doxorubicin Bleomycin Etoposide Gefitinib Daunorubicin Lomustine Sorafenib Sunitinib Ifosfamide Asparaginase Ixabepilone Abiraterone Azacitidine Ruxolitinib Decitabine Axitinib Estramustine Floxuridine Lapatinib Carmustine Fludarabine Nilotinib Cisplatin Vismodegib Vandetanib Melphalan Busulfan Carboplatin Toremifene Crizotinib Dactinomycin Temsirolimus Vorinostat Romidepsin Fluorouracil Irinotecan Bortezomib Tamoxifen Topotecan Chlorambucil Pentostatin Eribulin Carfilzomib Vemurafenib Hydroxyurea Exemestane Vincristine Sulfate Dasatinib Mitoxantrone Vinblastine Cytarabine Tretinoin Clofarabine Teniposide Docetaxel Pazopanib Oxaliplatin Streptozocin Paclitaxel Bendamustine Mechlorethamine Mitotane Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma Completed USA 0
NCT03582475 Phase I Etoposide Carboplatin + Docetaxel + Etoposide + Pembrolizumab Cisplatin + Etoposide + Pembrolizumab Pembrolizumab Carboplatin + Etoposide + Pembrolizumab Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate Active, not recruiting USA 0


Additional content available in CKB BOOST